Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMMP

Immutep Limited

Healthcare · Biotechnology

$3.63

Down-$0.21 (-5.47%)

Updated Oct 10, 2026, 4:25 AM

SID Score

6.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
388.59M
P/E ratio
-9.02
Dividend yield
0.00%
52-week range
$0.28 – $5.92
Volume
23.41K
Avg. volume
634.76K

Price performance · IMMP

IMMP price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

IMMP closed at $3.63 after 21 trading sessions, up 872.41% for the selected period.

Last close
$3.63
Period change
+872.41%
Period low
$0.29
Period high
$5.66
Daily close
View OHLC price history
IMMP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$3.785$3.785$3.55$3.6323.41K
Oct 8, 2026$4.02$4.1036$3.80$3.8414.9K
Oct 7, 2026$4.28$4.31$4.04$4.069.61K
Oct 6, 2026$4.34$4.51$4.30$4.3411.62K
Oct 5, 2026$4.35$4.50$4.18$4.2725.19K
Oct 2, 2026$4.61$4.61$4.165$4.3548.66K
Oct 1, 2026$4.70$4.70$4.53$4.5411.14K
Sep 30, 2026$4.79$4.79$4.6201$4.6510.5K
Sep 29, 2026$4.87$4.87$4.60$4.7134.04K
Sep 28, 2026$5.36$5.36$4.67$4.8849.15K
Sep 25, 2026$5.56$5.56$5.122$5.2733.26K
Sep 24, 2026$5.38$5.38$5.13$5.2412.07K
Sep 23, 2026$5.70$5.70$5.252$5.32237.58K
Sep 22, 2026$5.916$5.916$5.602$5.6627.48K
Sep 21, 2026$0.281$0.2969$0.2801$0.2913357.65K
Sep 18, 2026$0.3104$0.3104$0.28$0.2877576.5K
Sep 17, 2026$0.326$0.3321$0.315$0.3169245.31K
Sep 16, 2026$0.3378$0.3378$0.3141$0.327256.67K
Sep 15, 2026$0.3398$0.3398$0.3291$0.3303368.49K
Sep 14, 2026$0.3418$0.349$0.3231$0.3311509.33K
Sep 11, 2026$0.3675$0.405$0.355$0.37333.21M

Latest IMMP news

The latest Smart Investors Daily articles mentioning IMMP.

Stock researchCompany · Overview

IMMP research

Overview

Company profile and research snapshot.

Company profile

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.25
Implied upside
—
Analysts
—
IMMP recent ratings
DateFirmRatingTarget
Sep 22, 2026BELL POTTER SECURITIESHold—
Sep 2, 2026JEFFERIESHold—
Mar 31, 2026BELL POTTER SECURITIESHold—
Mar 30, 2026BELL POTTER SECURITIESHold—
Mar 2, 2026JEFFERIESBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Immutep Receives ~A$0.86 Million R&D Tax Incentive

SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year. This follows approval from AusIndustry of Immu

Yahoo · Sep 21, 2026

Change to American Depositary Share Ratio

SYDNEY, AUSTRALIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a change to the ratio of its American Depositary Shares (“ADSs”), which are quoted on the Nasdaq Global Market under the symbol IMMP. With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Eastern time), the ADS ratio will change from one

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By